

Curriculum Vitae

Personal information **Torsten Holm Nielsen**

Work experience

1. Employer: Danish Medicines Agency/Lægemiddelstyrelsen

1.
 - Start date: 072022
 - End date:
 - Position: Senior Medical Officer
 - Activities: Assessment/approval of anti-cancer (hematological) medicines. Member of SAWP (from Feb 2024).
 - Country: Denmark

2. Employer: Department of Hematology, Zealand University Hospital, Roskilde

1.
 - Start date: 092023
 - End date:
 - Position: Senior registrar/Afdelingslæge
 - Activities: Medical doctor, research
 - Country: Denmark

3. Employer: Department of Hematology, Copenhagen University Hospital, Rigshospitalet

1.
 - Start date: 112021
 - End date: 062022
 - Position: Senior registrar/Afdelingslæge
 - Activities: Medical doctor, Team for lymphoid malignancies.
 - Country: Denmark

4. Employer: Department of Hematology, Copenhagen University Hospital, Herlev

1.
 - Start date: 032020
 - End date: 102021

- Position: Senior registrar/Afdelingslæge
 - Activities: Medical doctor, Team for lymphoid malignancies.
 - Country: Denmark
5. Employer: Department of Hematology, Rigshospitalet, Copenhagen University Hospital
1.
 - Start date: 032018
 - End date: 022020
 - Position: Senior resident/ 1. reservelæge
 - Activities: Specialization in Internal medicine/ Hematology.
 - Country: Denmark
6. Employer: Department of Hematology, Copenhagen University Hospital, Herlev
1.
 - Start date: 032016
 - End date: 022018
 - Position: Resident/ Reservelæge
 - Activities: Specialization in Internal medicine/ Hematology.
 - Country: Denmark
7. Employer: Department of Cardiology, Zealand University Hospital, Roskilde
1.
 - Start date: 092015
 - End date: 022016
 - Position: Resident/ Reservelæge
 - Activities: Specialization in Internal medicine/ Hematology.
 - Country: Denmark
8. Employer: Department of Internal Medicine, Zealand University Hospital, Roskilde
1.
 - Start date: 032015
 - End date: 082015
 - Position: Resident/ Reservelæge
 - Activities: Specialization in Internal medicine/ Hematology.
 - Country: Denmark
9. Employer: Department of Hematology, Copenhagen University Hospital, Herlev
1.
 - Start date: 032014

- End date: 022015
 - Position: Resident/ Reservelæge
 - Activities: Hematology.
 - Country: Denmark
10. Employer: Department of Hematology, Zealand University Hospital, Roskilde
1.
 - Start date: 032013
 - End date: 022014
 - Position: Resident/ Reservelæge
 - Activities: Introduction to Hematology.
 - Country: Denmark
11. Employer: Björkhammars hälsocentral, Hammarstrand, Ragunda Kommun
1.
 - Start date: 042008
 - End date: 072008
 - Position: General practice
 - Activities: General practice/ family medicine and Accidents & Emergency medicine.
 - Country: Sweden
12. Employer: General practitioners Berntsen & Tolstrup, Nexø
1.
 - Start date: 092007
 - End date: 022008
 - Position: Resident (turnus)
 - Activities: General practice/ family medicine.
 - Country: Denmark
13. Employer: Department of Surgery, Bornholms Hospital, Rønne
1.
 - Start date: 032007
 - End date: 082007
 - Position: Resident (turnus)
 - Activities: General surgery and Accidents & Emergencies medicine.
 - Country: Denmark
14. Employer: Department of Internal Medicine, Bornholms Hospital, Rønne
1.
 - Start date: 102006

- End date: 022007
- Position: Resident (turnus)
- Activities: Internal medicine and Accidents & Emergencies medicine.
- Country: Denmark

Education and training

1. Subject: McGill University, Montréal
 - Start date: 092008
 - End date: 022013
 - Qualification: PhD, Experimental medicine
 - Organisation: Translational research in relapsed/refractory B-cell lymphoma. Correlative (lab) studies in conjunction with a phase 2 trial.
 - Country: Canada
2. Subject: University of Copenhagen
 - Start date: 021999
 - End date: 062006
 - Qualification: Medical school
 - Organisation: Medicine
 - Country: Denmark

Additional information

Publications

- Tolley ER, Lewinter C, Pedersen LM, Nielsen TH. Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: a systematic review and meta-analysis. *Haematologica*. 2024. doi: 10.3324/haematol.2023.284281.
- Østergaard S, Schejbel L, Breinholt MF, Pedersen MØ, Hammer T, Munksgaard L, et al. Mutational landscape in Waldenström macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice. *Leuk Lymphoma*. 2024. doi: 10.1080/10428194.2024.2313623.
- Micas Pedersen S, Feltoft CL, Nielsen TH, de Nully Brown P, Gang AO, Pedersen LM, Jørgensen N. Men treated with BEACOPP for Hodgkin lymphoma may be at increased risk of testosterone deficiency. *Ann Hematol*. 2024. doi: 10.1007/s00277-023-05512-y.
- Breinholt MF, Schejbel L, Gang AO, Nielsen TH, Pedersen LM, Høgdaal E, et al. Next generation sequencing in routine diagnostics of mature non-Hodgkin's B-cell lymphomas. *Eur J Haematol*. 2023. doi: 10.1111/ejh.14048.
- Hersby DS, Schejbel L, Breinholt MF, Høgdaal E, Nørgaard P, Dencker D, et al. Multi-site pre-therapeutic biopsies demonstrate genetic heterogeneity in patients with newly diagnosed diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2023. doi: 10.1080/10428194.2023.2220454.
- Micas Pedersen S, Nielsen TH, Gang AO, Poulsen CB, de Nully Brown P, Jørgensen N, et al. Sexual dysfunction is highly prevalent in male survivors of malignant lymphoma. *Sex Med*. 2023. doi: 10.1093/sexmed/qfad021.
- Al-Mashhadi AL, Cederleuf H, Jensen RK, Nielsen TH, Pedersen MB, Mortensen TB, et al. Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(-like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group. *Am J Hematol*. 2023. doi: 10.1002/ajh.26803
- Bhatti K, Nazir A, Ostergaard S, Schejbel L, Norgaard P, Gjerdrum LMR, et al. Bone Involvement as a Primary Rare Manifestation of Waldenström Macroglobulinemia: A Case Report and Prevalence in a Nationwide Population-Based Cohort Study. *J Hematol*. 2022. doi: 10.14740/jh1073.
- Schejbel L, Breinholt MF, Gang AO, Nielsen TH, Pedersen LM, Høgdaal E, et al. Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort: Strong correlation with BCL2 translocation. *eJHaem* 2022. <https://doi.org/10.1002/jha2.489>
- Lewinter C, Nielsen TH, Edfors LR, Linde C, Bland JM, LeWinter M, et al. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. *Eur Heart J*. 2021. doi: 10.1093/eurheartj/ehab843.
- Hersby DS, Do TH, Gang AO, Nielsen TH. COVID-19-associated pancytopenia can be self-limiting and does not necessarily warrant bone marrow biopsy for the purposes of SARS-CoV-2 diagnostics. *Ann Oncol*. 2021. doi: 10.1016/j.annonc.2020.09.020.
- Dupéré_Richer D, Kinal M, Pettersson F, Emond A, Calvo-Vidal MN, Nichol JN, et al. Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors. *Leuk Lymphoma*. 2017. doi: 10.1080/10428194.2016.1180684.
- Assouline SE, Nielsen TH, Yu S, Alcaide M, Chong L, MacDonald D, et al. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. *Blood*. 2016. doi: 10.1182/blood_2016_02_699520.
- Morin RD, Assouline S, Alcaide M, Mohajeri A, Johnston RL, Chong L, et al. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas. *Clin Cancer Res*. 2016. doi: 10.1158/1078_0432.CCR_15_2123.
- Nielsen TH, Diaz Z, Christodoulouopoulos R, Charbonneau F, Qureshi S, Rousseau C, et al. Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trials. *Cancer Epidemiol Biomarkers Prev*. 2014. doi: 10.1158/1055_9965.EPI_14_0549.
- Hariri F, Arguello M, Volpon L, Culjkovic-Kraljic B, Nielsen TH, Hiscott J, et al. The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia. *Leukemia*. 2013. doi: 10.1038/leu.2013.73.
- Nielsen TH, Johnson N, Garnier N, Kwan S, Yao L, Cocolakis E, et al. Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient. *Front Pharmacol*. 2013. doi: 10.3389/fphar.2013.00009.
- Dupéré_Richer D, Kinal M, Ménasché V, Nielsen TH, Del Rincon S, Pettersson F, et al. Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance. *Cell Death Dis*. 2013. doi:

Projects

Primary research interest is in the area of (B-cell) lymphomas. PhD-thesis on the topic of epigenetic therapy in relapsed diffuse large B-cell lymphoma (DLBCL).

Co-supervisor for 3 phd-students (all on-going and all at University of Copenhagen). Brief project descriptions: 1. Investigating the use of novel high-throughput analyses in the diagnosis of CNS-relapse of DLBCL 2. Investigating intra-tumoral heterogeneity in DLBCL. 3. Investigating the use of patient reported outcome measures in follow-up (relapse monitoring) of DLBCL. I have previously received funding from A.P. Møller and Chastine Mc_Kinney Møller Foundation, the LM Byg Foundation and the Sejer and Lis Klüwer Persson Foundation. No current funding.

Memberships

Danish Society of Hematology - member.

Other Relevant Information

Co-author of the current Danish national follicular lymphoma guideline:
[DLG_Follikulaert_lymfom_v2.0_AdmGodk100622.pdf \(lymphoma.dk\)](#)